Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Focus on Optimized Dosing of Ibrutinib Panel Discussion

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Oct

Today In Oncology

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Focus on Optimized Dosing of Ibrutinib Panel Discussion

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Long-Term Disease Control From SBRT Equal to Surgery in Localized Prostate Cancer

Prostate Cancer Higher Saturated Fat Intake May Be Linked to Worse Outcomes

The Wistar Institute Names New President and Chief Executive Officer

Early Research Links Abdominal Obesity to Increased Lung Cancer Risk

HER2-Negative Advanced Gastric Cancers First-Line Retlirafusp Alfa Combination Demonstrates Survival Benefit